Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Interest Expense

Cost of servicing the company's debt during the period.

Nuvalent, Inc.NASDAQ: NUVL

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $12.87M, compared with $0 a year earlier. Trailing-twelve-month interest expense was $12.87M.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $12.87M or moves back toward the trailing-twelve-month quarterly average of $3.22M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.87M— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$12.87M— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
NUVL Competitors
Interest Expense for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$124.82M USD+35.5%+26.6%175.9%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$100.31M USD-50.1%-12.2%2.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$93.71M USD+4.9%+72.3%20.8%
ABVXAbivax S.A.FY2025€28.48M EUR+129.1%+60.1%—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$18.23M USD-14.9%+58.2%6.5%
NUVLNuvalent, Inc.LTM Mar 2026$12.87M USD———
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$5.02M USD-40.6%-3.7%0.6%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 USD——0.0%
Peer median (excluding NUVL) —-5.0%+42.4%4.3%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.